Fifty years of hairy cell leukemia treatments.

Abstract:

:Treatment of hairy cell leukemia (HCL), a disease first described in 1958, has evolved from splenectomy, which resulted in a normalization of blood counts in about 41% of patients and an improvement in the remaining 59% of patients but with a time to failure of only approximately 19 months, through treatment in the early 1980s with interferon, which resulted in the same high overall response rate but with a time to failure of approximately 31 months. Subsequently, therapy with either pentostatin or cladribine showed an increase in the complete remission (CR) rate to approximately 80-90%, with only a small percentage of patients relapsing at approximately 30 months. More recently, patients who have failed either or both of these drugs have been shown to respond to rituximab or the experimental drug, BL22 (HA22). With these documented successes, the outlook for patients diagnosed with HCL, 50 years after the disease was first described, is so positive that patients with HCL have survival curves similar to those for the appropriate age-related cohorts.

journal_name

Leuk Lymphoma

journal_title

Leukemia & lymphoma

authors

Golomb HM

doi

10.3109/10428194.2011.565094

subject

Has Abstract

pub_date

2011-06-01 00:00:00

pages

3-5

eissn

1042-8194

issn

1029-2403

journal_volume

52 Suppl 2

pub_type

杂志文章,评审
  • Therapeutic experience of adult acute myeloid leukemia in a single institution of China and its relationship with chromosome karyotype.

    abstract::One hundred and ninety-six untreated de novo acute myeloid leukemia (AML) patients were treated with homoharringtonine + cytosine arabinoside (HA) based induction therapy composed of three chemotherapeutic drugs (HAD/M, D-daunorubicin-DNR, M-mitozantrone-MTZ) used in our hospital for the past 12 years. The patient pop...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190701836852

    authors: Mi Y,Xue Y,Yu W,Liu S,Zhao Y,Meng Q,Bian S,Wang J

    更新日期:2008-03-01 00:00:00

  • Clinical features and prognostic factors of angioimmunoblastic T-cell lymphoma in Taiwan: a single-institution experience.

    abstract::Angioimmunoblastic T-cell lymphoma (AITL) is a rare subtype of peripheral T-cell lymphoma that carries a poor prognosis. This study retrospectively analyzed patients with AITL from a single institution in Taiwan, aiming to define the clinical features and prognostic factors. Patients with AITL treated at our instituti...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2010.525270

    authors: Lin HN,Liu CY,Hong YC,Pai JT,Yang CF,Yu YB,Hsiao LT,Chiou TJ,Liu JH,Gau JP,Tzeng CH,Chen PM

    更新日期:2010-12-01 00:00:00

  • Ubiquitin ligases in malignant lymphoma.

    abstract::The highly controlled degradation of proteins via the ubiquitin-proteasome pathway represents a key mechanism for cell regulation and homeostasis. Ubiquitin-dependent proteolysis, carried out in large part by the E3 ubiquitin ligases, is a critical mode of post-translational modification that is important in regulatio...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190410001663635

    authors: Lim MS,Elenitoba-Johnson KS

    更新日期:2004-07-01 00:00:00

  • Familial Lymphoproliferative Disorders with Chromosomal Fragile Site Analysis.

    abstract::We have identified a family in which three members developed B-cell lymphoproliferative disorders within a nine month period. The 33 year old proband and his mother have hairy cell leukemia, and his 37 year old brother developed a large cell lymphoma. Chromosomal fragile site analysis of peripheral blood lymphocytes o...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199109067623

    authors: Moormeier JA,Neilly ME,Vardiman JW,Le Beau MM,Golomb HM

    更新日期:1991-01-01 00:00:00

  • Efficacy and safety of gemtuzumab ozogamicin in patients with poor-prognosis acute myeloid leukemia.

    abstract::The objective of this work was to determine the safety and efficacy of gemtuzumab ozogamicin in patients with poor prognosis acute myeloid leukemia (AML). Patients with the following diagnoses/characteristics were treated with 1-3 infusions of gemtuzumab ozogamicin at a dose of 9 mg/m2: (1) relapse of AML < or = 6 mon...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章

    doi:10.1080/1042819021000016078

    authors: Roboz GJ,Knovich MA,Bayer RL,Schuster MW,Seiter K,Powell BL,Woodruff RD,Silver RT,Frankel AE,Feldman EJ

    更新日期:2002-10-01 00:00:00

  • IKZF1 rs4132601 polymorphism and acute lymphoblastic leukemia susceptibility: a meta-analysis.

    abstract::Several studies have been conducted to examine the association between IKZF1 rs4132601 polymorphism and acute lymphoblastic leukemia (ALL) risk. However, the conclusions remain controversial. We therefore performed a meta-analysis. PubMed, Embase, Web of Science, Weipu and Chinese Biomedical Literature (CBM) databases...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,meta分析

    doi:10.3109/10428194.2014.939965

    authors: Li S,Ren L,Fan L,Wang G

    更新日期:2015-04-01 00:00:00

  • Idiopathic primary osteo-myelofibrosis: a clinico-pathological study on 208 patients with special emphasis on evolution of disease features, differentiation from essential thrombocythemia and variables of prognostic impact.

    abstract::A retrospective clinico-pathological study was performed on 208 consecutively recruited patients (94 males, 114 females, median age 67 years) with idiopathic (primary) osteo-/ myelofibrosis (IMF). According to bone marrow histology (cellularity) as well as extent (semiquantitative grading) and quality (reticulin/colla...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199609051762

    authors: Thiele J,Kvasnicka HM,Werden C,Zankovich R,Diehl V,Fischer R

    更新日期:1996-07-01 00:00:00

  • Proposals for a Phenotypic Classification of B-Chronic Lymphocytic Leukemia, Relationship with Prognostic Factors.

    abstract::Immunophenotypic analysis was performed in 53 cases of B chronic lymphocytic leukemia using a large panel of monoclonal antibodies recognizing B, T, activation and myeloid antigens. Our results showed four patterns of reactivity: (a) several molecules were constantly expressed: CD19, CD20, CD24, CD37, HLA-DR, mu heavy...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199109103379

    authors: Legac E,Chastang C,Binet JL,Michel A,Debre P,Merle-Beral H

    更新日期:1991-01-01 00:00:00

  • Primary Non-Hodgkin's Lymphomas of the Nasal and Mouth Cavity and the Waldeyer's Ring: A morphological and immunohistochemical study.

    abstract::Twenty-six non-Hodgkin's malignant lymphomas (ML) of the Waldeyer's ring, the mouth and nasal cavities were studied morphologically and immunohistochemically on paraffin and frozen sections. A B-cell origin was shown in all 14 cases of Waldeyer's ring M.L., while 5 of 7 nasal and 3 of 5 buccal cases were of T-cell nat...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199109070283

    authors: Papadimitriou CS,Bai MK

    更新日期:1991-01-01 00:00:00

  • Molecular remission following high-dose hydroxyurea and fludarabine plus cytarabine in a patient with simultaneous acute myeloid leukemia and low-grade lymphoma.

    abstract::The occurrence of acute myeloid leukemia (AML) as a secondary tumor has been frequently reported in patients who received various chemotherapy regimens for hematologic malignancies wile the concomitant development of chronic lymphoproliferative diseases (CLD) and AML in previously untreated patients is extremely rare....

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190109097666

    authors: Montefusco E,Fazi F,Cordone I,Ariola C,Nanni M,Spadea A,Spiriti MA,Fenu S,Mandelli F,Petti MC

    更新日期:2001-02-01 00:00:00

  • Large scale manufacturing of B43(anti-CD19)-genistein for clinical trials in leukemia and lymphoma.

    abstract::We have conjugated the murine monoclonal anti-CD19 antibody B43 to the tyrosine kinase inhibitor genistein to construct an effective immunoconjugate against CD19 antigen positive hematologic malignancies. The scaled-up production and purification of B43 antibody, genistein, and B43-Genistein immunoconjugate permitted ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199809068569

    authors: Myers DE,Sicheneder A,Clementson D,Dvorak N,Venkatachalam T,Sev AR,Chandan-Langlie M,Uckun FM

    更新日期:1998-04-01 00:00:00

  • Long-term follow-up of Asian patients younger than 46 years with acute myeloid leukemia in first complete remission: comparison of allogeneic vs. autologous hematopoietic stem cell transplantation.

    abstract::Optimal therapy for patients with acute myeloid leukemia (AML) in first complete remission (CR-1) remains the subject of debate: with the possibilities of chemotherapy alone, autologous (auto) or allogeneic (allo) hematopoietic stem cell transplantation (HSCT). We undertook a retrospective analysis of AML patients age...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190601040357

    authors: Loh YS,Koh LP,Tai BC,Hwang WY,Linn YC,Goh YT,Tan PH

    更新日期:2007-01-01 00:00:00

  • Primary granulocytic sarcoma of ovary--a rare presentation.

    abstract::Granulocytic sarcomas (GS) are rare extra medullary tumors composed of myeloid progenitor cells. Bones, lymph nodes and skin are favored sites of involvement. Primary involvement of the ovary is exceedingly rare leading to under diagnosis of GS. We report on a 19-year-old woman who presented with an ovarian mass witho...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190312001623892

    authors: Mehta J,Kane S

    更新日期:2004-04-01 00:00:00

  • Effects of induction with novel agents versus conventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma.

    abstract::Multiple myeloma (MM) is the top indication for high-dose chemotherapy (HDC) with autologous stem cell transplantation (SCT), a strategy which improves progression-free survival and potentially overall survival (OS). Novel induction regimens incorporating the immunomodulatory (IMID) agents, such as thalidomide and len...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190903480728

    authors: Benson DM Jr,Panzner K,Hamadani M,Hofmeister CC,Bakan CE,Smith MK,Elder P,Krugh D,O'Donnell L,Devine SM

    更新日期:2010-02-01 00:00:00

  • Treatment of refractory T-cell chronic lymphocytic leukemia with purine nucleoside analogues.

    abstract::This report describes two cases of T-cell chronic lymphocytic leukemia (T-CLL) treated with purine nucleoside analogues. One patient had CD8+, CD3+ large granular lymphocytosis (LGL) producing transfusion-dependent anemia and was refractory to chemotherapy. Treatment with four cycles of fludarabine produced a clinical...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199409049659

    authors: Witzig TE,Weitz JJ,Lundberg JH,Tefferi A

    更新日期:1994-06-01 00:00:00

  • Detection of platelet-specific protein mRNAs in different megakaryoblasts using the reverse transcriptase polymerase chain reaction.

    abstract::The short segments of cDNA encoding glycoprotein (GP)Ib alpha, GPIIb, GPIIIa and platelet factor (PF) 4 were amplified using reverse transcriptase-polymerase chain reaction (RT-PCR) in order to characterize various types of megakaryoblasts. Cell lines with megakaryocytic features (K562, CMK and HEL) were tested. GPIb ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199209049808

    authors: Yasunaga M,Ryo R,Sugano W,Yamaguchi N

    更新日期:1992-08-01 00:00:00

  • Efficacy of selective digestive decontamination in patients with multiple myeloma undergoing high-dose chemotherapy and autologous stem cell transplantation.

    abstract::Selective digestive decontamination (SDD) with the oral, non-absorbable antimicrobial substances gentamicin, vancomycin and amphotericin B was optionally used at our institution to reduce the risk of gastrointestinal tract derived infections in multiple myeloma (MM) patients undergoing high-dose chemotherapy with subs...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2018.1496332

    authors: Mürner CM,Stenner-Liewen F,Seifert B,Mueller NJ,Schmidt A,Renner C,Schanz U,Knuth A,Manz MG,Scharl M,Gerber B,Samaras P

    更新日期:2019-03-01 00:00:00

  • STAT3, tumor microenvironment, and microvessel density in diffuse large B cell lymphomas.

    abstract::Constitutively activated STAT3 is correlated with more advanced clinical stage and overall poor survival of diffuse large B-cell lymphoma (DLBCL). The aim of this study was to evaluate STAT3 and Ki67 tumor cell expression, inflammatory cell infiltration, microvascular density in DLBCL bioptic specimens. RNA-scope show...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2019.1678154

    authors: Tamma R,Ingravallo G,Gaudio F,Annese T,Albano F,Ruggieri S,Dicataldo M,Maiorano E,Specchia G,Ribatti D

    更新日期:2020-03-01 00:00:00

  • Combined therapeutic efficacy of the thymidylate synthase inhibitor ZD1694 (Tomudex) and the immunotoxin B43(anti-CD19)-PAP in a SCID mouse model of human B-lineage acute lymphoblastic leukemia.

    abstract::The quinazoline antifolate N-(5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N- methylamino]-2-thenoyl)-L-glutamic acid (ZD1694; Tomudex) is a potent inhibitor of thymidylate synthase and causes cell death through disruption of DNA synthesis and repair by blocking the obligatory thymidine nucleotide synthesis....

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199809058358

    authors: Ek O,Reaman GH,Crankshaw DL,Chelstrom LM,Myers DE,Uckun FM

    更新日期:1998-02-01 00:00:00

  • Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation.

    abstract::We aimed to identify whether the use of autologous hematopoietic cell transplantation (HCT) impacts outcomes for multiple myeloma patients with gains of chromosome 1q (+1q). We retrospectively identified 95 patients, 21% having +1q. For patients with +1q, the overall response rate to induction was 85%, with 40% having...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2016.1260126

    authors: Shah GL,Landau H,Londono D,Devlin SM,Kosuri S,Lesokhin AM,Lendvai N,Hassoun H,Chung DJ,Koehne G,Jhanwar SC,Landgren O,Levine R,Giralt SA

    更新日期:2017-08-01 00:00:00

  • Angiogenesis and anti-angiogenic therapy in myelofibrosis with myeloid metaplasia.

    abstract::Myelofibrosis with myeloid metaplasia (MMM) is a clonal stem cell disorder that is characterized by florid bone marrow stromal reaction including collagen fibrosis, osteosclerosis, and angiogenesis. Almost all patients with MMM display increased bone marrow microvessel density (MVD) and the extent is among the highest...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190400003267

    authors: Arora B,Mesa R,Tefferi A

    更新日期:2004-12-01 00:00:00

  • Acute myeloid leukemia outcome: role of nucleotide excision repair polymorphisms in intermediate risk patients.

    abstract::In acute myeloid leukemia (AML), cytogenetics predicts treatment outcome for the favorable and poor subgroups but not for the intermediate subgroup. Polymorphisms within the nucleotide excision repair (NER) pathway may lead to interindividual differences in DNA repair capacity, influencing outcome. We studied the role...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190903582804

    authors: Strom SS,Estey E,Outschoorn UM,Garcia-Manero G

    更新日期:2010-04-01 00:00:00

  • DNMT3A co-mutation is required for FLT3-ITD as an adverse prognostic indicator in intermediate-risk cytogenetic group AML.

    abstract::This single institution cohort study of 132 AML patients investigated the clinical implications of co-mutations detected with a 42-gene NGS panel. In the intermediate-risk cytogenetic group, FLT3-ITD is an adverse prognostic indicator only in the presence of a DNMT3A co-mutation, regardless of NPM1 mutation status. In...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2017.1397659

    authors: Ma J,Dunlap J,Paliga A,Traer E,Press R,Shen L,Fan G

    更新日期:2018-08-01 00:00:00

  • Detection of respiratory viruses with a multiplex polymerase chain reaction assay (MultiCode-PLx Respiratory Virus Panel) in patients with hematologic malignancies.

    abstract::Respiratory viral pathogens are a common cause of morbidity in patients with hematologic malignancies. Sensitive molecular assays have increased the detection of common respiratory viruses and expanded the panel of detectable viruses. Both a rapid viral culture with direct fluorescence antibody (DFA) staining and a PC...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190902777665

    authors: Murali S,Langston AA,Nolte FS,Banks G,Martin R,Caliendo AM

    更新日期:2009-04-01 00:00:00

  • An open-label, pharmacokinetic study of lenalidomide and dexamethasone therapy in previously untreated multiple myeloma (MM) patients with various degrees of renal impairment - validation of official dosing guidelines.

    abstract::Lenalidomide is a backbone agent in the treatment of multiple myeloma, but dose adjustment is required for those with renal impairment (RI). We evaluated the pharmacokinetics (PK) and safety of lenalidomide and dexamethasone as frontline pre-transplant induction, with doses adjusted at start of each cycle based on cre...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1747064

    authors: Chen CI,Cao Y,Trudel S,Reece DE,Kukreti V,Tiedemann R,Prica A,Paul H,Le LW,Levina O,Kakar S,Lau A,Chen H,Chen E

    更新日期:2020-08-01 00:00:00

  • Genomic stratification of multiple myeloma treated with novel agents.

    abstract::Cytogenetic testing is now routinely performed for the prognostic work-up of multiple myeloma (MM). The abnormalities del(17p), t(4;14) and del(13q) have been established as predictors of poor outcome in patients with MM treated with conventional chemotherapy or stem cell transplant; chromosome 1q gains and 1p losses ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428194.2011.608449

    authors: Jiang A,Reece D,Chang H

    更新日期:2012-02-01 00:00:00

  • Suicide gene-mediated modulation of graft-versus-host disease.

    abstract::The development of suicide genes and progress in retroviral gene transfer to T-cells open new perspectives for the treatment of graft-versus-host disease (GVHD) after allogeneic bone marrow transplantation (BMT) for leukemia and lymphoma. Indeed, suicide genes that metabolize inactive prodrugs into compounds toxic for...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199909058474

    authors: Cohen JL,Boyer O,Thomas-Vaslin V,Klatzmann D

    更新日期:1999-08-01 00:00:00

  • Comparison of two functional flow cytometric assays to assess P-gp activity in acute leukemia.

    abstract::One of the possible causes of treatment failure in acute leukemia is the emergence of multidrug resistance caused by P-glycoprotein (P-gp) overexpression. We compared a flow cytometric assay using JC-1 with a technique using rhodamine 123 (rho123) to evaluate the P-gp function in acute leukemia. Samples from 50 acute ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190412331272767

    authors: Swerts K,de Moerloose B,Dhooge C,Noens L,Laureys G,Benoit Y,Philippé J

    更新日期:2004-11-01 00:00:00

  • Allergic reactions associated with pegaspargase in adults.

    abstract::One of the severe toxicities of pegaspargase (PEG) is the development of allergic reactions. This study retrospectively assessed 311 PEG doses administered to 139 acute lymphoblastic leukemia patients from May 1, 2008 to July 30, 2014 for allergic reactions based on the Common Terminology Criteria for Adverse Events (...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2015.1105369

    authors: Chang A,Kim M,Seyer M,Patel S

    更新日期:2016-07-01 00:00:00

  • Leukemic leptomeningeal involvement in stage 0 and stage 1 chronic lymphocytic leukemia.

    abstract::Central nervous system (CNS) involvement in early (Rai Stage 0 and Stage 1) chronic lymphocytic leukemia (CLL) is rare, with only five cases reported. We present the sixth reported case, a 77-year-old male with a 4 year history of Stage 0 CLL who presented with sudden onset of diplopia and headache. Workup revealed a ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190210191

    authors: Brick WG,Majmundar M,Hendricks LK,Kallab AM,Burgess RE,Jillella AP

    更新日期:2002-01-01 00:00:00